The Senza system delivers Nevro's HF10 ™ SCS therapy, which provides electrical pulses to the spinal cord at a rate up to 10 kHz to reduce the sensation of pain. The electrical pulses are conveyed by small electrodes placed near the spinal cord and connected to a compact battery-powered generator implanted under the skin. Data from this and other European clinical studies suggest that Nevro's HF10 SCS therapy may offer the ability to treat low back pain and other challenging conditions, including chronic pain patients who do not respond to traditional low-frequency SCS therapy.
The Senza system is presently the subject of the SENZA-RCT study, a prospective, randomized, controlled pivotal study in the United States to further evaluate the safety and efficacy of Nevro's Senza system in patients with chronic pain. The unblinded study will enroll up to approximately 300 patients at up to 15 leading pain centers across the U.S. and will compare its performance against treatment with traditional low-frequency SCS. In the United States, the system is limited by federal law to investigational use and is not available for promotion or sale.
About Nevro Corp.
Headquartered in Menlo Park, California, privately held Nevro Corp. is focused on the development and commercialization of high-frequency spinal cord stimulation (HF-SCS) for the treatment of chronic pain and other disorders. The company has developed the Senza HF-SCS system, only SCS system capable of delivering stimulation of up to 10 kHz and providing HF10 SCS therapy. The company's proprietary high-frequency waveform technology appears unique in its potential to effectively treat challenging conditions such as low back pain while enhancing patient experience. Nevro's investors include Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, Johnson & Johnson Development Corporation, MPM Capital, and Three Arch Partners. For more information, please visit www.nevro.com.Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.